Published by Coherent Market Insights
Posted on September 27, 2021
5 min readLast updated: February 2, 2026
The Gonorrhea Diagnostic Market is set for growth by 2027, driven by high STI prevalence and innovative diagnostic tools like PROMPT.
The Gonorrhea Diagnostic Market is predicted to possess a highly positive outlook over the forecast period 2021-2027 consistent with a research report. The report stresses the foremost recent advancements, development, new chances, and growth. It gives a comprehensive position of the Gonorrhea Diagnostic. The Gonorrhea Diagnostic research report covers this scenario and therefore the growth prospects of the worldwide Gonorrhea Diagnostic Industry for 2021-2027. The report enlists several important factors, ranging from the fundamentals to advanced market intelligence which plays an important part in strategizing. Gonorrhea Diagnostic manufacturers and may be a valuable source of guidance and direction for companies and individuals curious about the Gonorrhea Diagnostic industry.
Get PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/126
Key Vendors of Gonorrhea Diagnostic Market:
Becton, Dickinson and Company, Baxter International, Inc., Pfizer Inc., B. Braun Melsungen AG, Fresenius SE & CO. KGaA, Medtronic plc, Smiths Group plc, Terumo Corporation, Moog, Inc., F. Hoffmann-la Roche Ltd., and Johnson & Johnson.
Gonorrhea is a sexually transmitted disease caused by a bacterium Neisseria Gonorrhoeae. It is one of the most common sexually transmitted diseases and affects millions of people each year. According to the study, ‘Global epidemiology of Neisseria gonorrhoeae in infertile populations: systematic review, meta-analysis and metaregression’, published in BMJ Journals in May 2020, the pooled mean prevalence of current gonorrhoea infection worldwide was at 2.2%, with the highest prevalence in Africa at 5.0%. Thus, high prevalence of gonorrhea in emerging economies is expected to propel growth of the gonorrhea diagnostic market.
Diagnostic tools available in the gonorrhea diagnostic market include urine test, swab test and nucleic acid amplification testing (NAAT). The gonorrhea diagnostic market is witnessing R&D of new approaches for diagnosis. In May 2021, researchers from Johns Hopkins University reported development of PROMPT (portable, rapid, on-cartridge, magnetofluidic purification and testing platform), an inexpensive portable device and a complimenting smartphone app that can diagnose gonorrhea infection in under 15 minutes. The study was published in Science Translational Medicine.
Emergence of Covid-19 has led to significant rise in sexually transmitted diseases, which is also expected to aid in growth of the gonorrhea diagnostic market. In November 2020, a study conducted in two main STI centers in Milan, Italy, revealed that diagnosis of STIs, including gonorrhea, secondary syphilis and mycoplasma genitalium (MG) has increased despite the lockdown restrictions. The study results were presented at the 29th European Academy of Dermatology and Venereology virtual conference.
Players in the gonorrhea diagnostic market are focused on expanding their distribution channel. In February 2021, Binx Health, a provider of point-of-care diagnostic solutions, partnered with McKesson, a healthcare company, for the sale and distribution of the Binx io molecular diagnostic testing platform in the US. The point-of-care platform enables the diagnosis and subsequent treatment of chlamydia and gonorrhea to take place in a single visit. Later, in April 2021, the Food and Drug Administration granted a CLIA waiver for the binx health io CT/NG assay, thereby allowing the use of the binx health io CT/NG assay at point-of-care settings.
The gonorrhea diagnostic market in North America is expected to witness significant growth with surge in cases of gonorrhea infections. According to a Michigan Department of Health and Human Services press release, in Michigan reported a 22% increase in reported gonorrhea infections for 2020 compared to 18,264 gonorrhea infections in 2019.
Gonorrhea Diagnostic Market Reports cover complete modest outlook with the market stake and company profiles of the important contestants working in the global market. The Gonorrhea Diagnostic Market offers a summary of product Information, production analysis, technology, product type, considering key features such as gross, gross margin, gross revenue, revenue, cost.
Key Stakeholders Covered within this Gonorrhea Diagnostic Market Report:
Lastly, this report covers the market Outlook and its growth prospects over the coming years, the Report also brief deals with the product life cycle, comparing it to the significant products from across industries that had already been commercialized details the potential for various applications, discussing about recent product innovations and gives an short summary on potential regional market.
Why this is Important Report to you? It helps:
To Buy Report (With USD 2000 Flat OFF), Click Here – https://www.coherentmarketinsights.com/promo/buynow/126
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post Gonorrhea Diagnostic Market: An Investor’s Guide to Understand Market Variation Globally appeared first on Gatorledger.
The article focuses on the growth and trends in the Gonorrhea Diagnostic Market globally from 2021 to 2027.
The article highlights the PROMPT device, a rapid diagnostic tool developed by Johns Hopkins University.
COVID-19 has led to a rise in STI cases, including gonorrhea, which is expected to drive market growth.
Explore more articles in the Research Reports category
